6British Journal of Urology International,2001;86:65-67.
7Brawer MK, Meyer GE, Letran JL, et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer[J]. Urology, 1998,52:372.
8Moul JW, Merseburger AS, Srivastava S. Molecular markers in prostate cancer: the role in preoperative staging [J]. Clin Prostate Cancer, 2002, 1 (1): 42-50.
9Irani J, Levillain P, Gouion JM, et al. Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value [J]. J Urol, 1997, 157 (4): 1301-1303.
10Douglas TH, Morgan TO, McLead DG, et al. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients [J]. Cancer, 1997, 80: 107-114.
2Epe P, Panella P, Savoca F, et al. Prevalence and clinical significance of prostate cancer among 12,682 men with normal digital rectal examination, low PSA levels (≤4 ng/mL) and percent free PSA cutoff values of 15 and 20q't[J]. Urol Int,2007, 78:308-312.
3Roddam AW, Rimmer J, Nickerson C, et al. Prostate-specific antigen: bias and molarity of commercial assays for PSA in use in England. Ann Clin Biochem, 2006,43:35-48.
4Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin,2007,57:43-66.
5Okegawa T, Kinjo M, Ohta M, et al. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL[J]. Int J Urol, 2003,10:201-206.
6Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter[J]. N Engl J Med, 2004,350: 2239-2246.
